Neprilysin inhibitors offer a new target for therapeutics. Neprilysin is an enzyme that degrades endogenous natriuretic peptides. [1] These peptides are secreted during times of fluid overload when ...

Neprilysin is a ubiquitous zinc-dependent endopeptidase that regulates the homeostasis of key vasoactive peptides, notably natriuretic peptides, bradykinin and adrenomedullin. By cleaving these ...

The current issue of Neuron contains a scientific debate that bears watching. It is about one of the great mysteries of amyloid-β precursor protein (APP), that is, its physiological role. Scientists ...

The approval of LCZ696 for the treatment of heart failure with reduced ejection fraction is the first for chronic neprilysin inhibitor therapy Neprilysin contributes to the formation and degradation ...

Neprilysin is one of multiple enzymes involved in the proteolytic degradation of amyloid β peptides associated with Alzheimer's type dementia and concern had been raised that their accumulation in the ...

Neprilysin, one of a handful of proteases known to degrade amyloid-β (Aβ), might seem an attractive therapeutic for Alzheimer disease (AD)—until you consider the difficulties of administration. Direct ...

We compared the angiotensin receptor–neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in ...

Alzheimer's Society has been following the research of Joanna Zukowska, supervised by Professor K. Ravi Acharya and Dr Vasanta Subramanian. Here, she explains her findings on Neprilysin and its effect ...

The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and ...

Barcelona, Spain – 26 Aug 2022: Sacubitril/valsartan does not change cognitive function, compared with valsartan, in patients with heart failure and mildly reduced or preserved ejection fraction, ...